AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33400078 — intervention group
Group type: COMPARATOR
Intervention: No supplemental education
Number of subjects: 787
Study 32201918 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight-based prednisolone regimen (2 mg/kg/day till remission, then 1.5 mg/kg on alternate days for 4 weeks)
Number of subjects: 60
Study 32201918 — intervention group
Group type: COMPARATOR
Intervention: Body surface area-based prednisolone regimen (60 mg/m2/day till remission, then 40 mg/m2 on alternate days for 4 weeks)
Number of subjects: 60
Study 35487525 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg orally for 6 months
Number of subjects: 40
Study 35487525 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 34950731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1.5 g, LCG)
Number of subjects: 9
Study 34950731 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose (3.0 g, MCG)
Number of subjects: 9
Study 34950731 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (6.0 g, HCG)
Number of subjects: 9
Study 34950731 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1.5 g, 3.0 g, 6.0 g)
Number of subjects: 9
Study 33753432 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of a pharmacist within general practice teams to optimise prescribing and medication-related activities.
Number of subjects: 120
Study 33753432 — intervention group
Group type: COMPARATOR
Intervention: Standard GP care (Control).
Number of subjects: 120
Study 33753432 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of a pharmacist within general practice teams.
Number of subjects: 120
Study 33475607 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated and fully equipped trauma care system
Number of subjects: 295589
Study 33475607 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict implementation of road traffic safety laws
Number of subjects: 295589
Study 35195932 — intervention group
Group type: EXPERIMENTAL
Intervention: Solacea-190H (ATA) dialyser
Number of subjects: 10
Study 35195932 — intervention group
Group type: COMPARATOR
Intervention: FX-80 dialyser
Number of subjects: 10
Study 34461975 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising Together™ (partnered strength training program)
Number of subjects: 294
Study 34461975 — intervention group
Group type: COMPARATOR
Intervention: Separate supervised group exercise classes for survivors or partners
Number of subjects: 294
Study 34461975 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home exercise program
Number of subjects: 294
Study 34461975 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising Together™
Number of subjects: 294
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication behavior
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of OTC drugs
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of risks of self-medication
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Health issues leading to self-medication
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of medication used
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for self-medication
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of self-medication
Number of subjects: 700
Study 32366238 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for self-medication
Number of subjects: 700
Study 35624004 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified aligner appliances with nickel‐titanium springs (MAAs)
Number of subjects: 36
Study 35624004 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed bracket group (control)
Number of subjects: 36
Study 34228250 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan treatment
Number of subjects: 1630
Study 32166429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 59
Study 32166429 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide (LEF) 20 mg daily
Number of subjects: 59
Study 32166429 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 59
Study 32166429 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide (LEF)
Number of subjects: 59
Study 33693561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks
Number of subjects: 60
Study 33693561 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 60
Study 32415423 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 60
Study 32415423 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study 33190008 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg per day sumac powder for 12 weeks
Number of subjects: 84
Study 33190008 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 84
Study 35972010 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical khat leaves
Number of subjects: 24
Study 35972010 — intervention group
Group type: COMPARATOR
Intervention: Frozen peas dressing (control)
Number of subjects: 24
Study 36109788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (4 weeks prior to and following vaccination)
Number of subjects: 0
Study 36109788 — intervention group
Group type: COMPARATOR
Intervention: Standard of care immunosuppression with tacrolimus, mycophenolate, and prednisolone (control)
Number of subjects: 0
Study 36109788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (intervention)
Number of subjects: 0
Study 33753456 — intervention group
Group type: EXPERIMENTAL
Intervention: fam-trastuzumab deruxtecan-nxki (T-DXd) at a dose of 5.4 mg/kg
Number of subjects: 184
Study 32460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care intervention (weekly)
Number of subjects: 100
Study 35248737 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected monitoring using a smartphone interface
Number of subjects: 89
Study 35248737 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 89
Study 35248737 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected monitoring
Number of subjects: 89
Study 33845345 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based remotely delivered self-management program (SMART)
Number of subjects: 0
Study 33845345 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group feedback
Number of subjects: 0
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blockade (NMB)
Number of subjects: 602
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: VR > 2 (median) at day 1
Number of subjects: 602
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: VR at day 1
Number of subjects: 602
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising VR trajectory
Number of subjects: 602
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline VR
Number of subjects: 602
Study 36175982 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE-III
Number of subjects: 602
Study 36175982 — intervention group
Group type: COMPARATOR
Intervention: NMB
Number of subjects: 602
Study 33766132 — intervention group
Group type: EXPERIMENTAL
Intervention: IWG‐2 prodromal AD
Number of subjects: 311
Study 33766132 — intervention group
Group type: EXPERIMENTAL
Intervention: NIA‐AA 2011 high AD likelihood
Number of subjects: 311
Study 33766132 — intervention group
Group type: EXPERIMENTAL
Intervention: NIA‐AA 2018 AD
Number of subjects: 311
Study 32804611 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids treatment in patients with initial C-reactive protein (CRP) ≥20 mg/dL
Number of subjects: 1806
Study 32804611 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids treatment in patients with CRP <10 mg/dL
Number of subjects: 1806
Study 32804611 — intervention group
Group type: COMPARATOR
Intervention: Early use of glucocorticoids
Number of subjects: 1806
Study 35295761 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional corticotomy (TC)
Number of subjects: 38
Study 35295761 — intervention group
Group type: COMPARATOR
Intervention: Flapless corticotomy (FC)
Number of subjects: 38
Study 35295761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TC and FC
Number of subjects: 38
Study 32634760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense (DD) chemotherapy
Number of subjects: 2003
Study 32634760 — intervention group
Group type: COMPARATOR
Intervention: Standard-interval (SI) chemotherapy
Number of subjects: 2003
Study 33648555 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week self-help intervention plus care as usual
Number of subjects: 80
Study 33648555 — intervention group
Group type: COMPARATOR
Intervention: 3-week waiting period with only care as usual
Number of subjects: 80
Study 32570661 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile App
Number of subjects: 350
Study 36273478 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose of antenatal betamethasone
Number of subjects: 0
Study 36273478 — intervention group
Group type: COMPARATOR
Intervention: Full dose of antenatal betamethasone
Number of subjects: 0
Study 32000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 10
Study 32000139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartan
Number of subjects: 10
Study 32000139 — intervention group
Group type: COMPARATOR
Intervention: Asphalt
Number of subjects: 10
Study 35658325 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate 1 mg with 500 mg calcium and 200 U vitamin D3
Number of subjects: 262
Study 35658325 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 500 mg calcium and 200 U vitamin D3
Number of subjects: 262
Study 35658325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 35658325 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 262
Study 35753878 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Error of Prediction (SEP)
Number of subjects: 2430
Study 35753878 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable Change Index (RCI)
Number of subjects: 2430
Study 35753878 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Error of Measurement (SEM)
Number of subjects: 2430
Study 35753878 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Error of Estimate (SEE)
Number of subjects: 2430
Study 34961905 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III liquid formulation by autoinjector (Treatment A)
Number of subjects: 24
Study 34961905 — intervention group
Group type: COMPARATOR
Intervention: Phase I/II reconstituted lyophilizate-based formulation by syringe (Treatment C)
Number of subjects: 24
Study 34961905 — intervention group
Group type: COMPARATOR
Intervention: Phase III liquid formulation by prefilled syringe (Treatment B)
Number of subjects: 24
Study 32434236 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 40
Study 32434236 — intervention group
Group type: COMPARATOR
Intervention: Without patellar resurfacing
Number of subjects: 40
Study 34971811 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping of the resection base
Number of subjects: 179
Study 34971811 — intervention group
Group type: COMPARATOR
Intervention: No clipping (Control)
Number of subjects: 179
Study 33464993 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on universal education and IPV assessment approach
Number of subjects: 98
Study 33464993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use screening
Number of subjects: 98
Study 33464993 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use screening
Number of subjects: 98
Study 33464993 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drug use screening
Number of subjects: 98
Study 33464993 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of IPV and substance use as intersecting health problems
Number of subjects: 98
Study 34158793 — intervention group
Group type: EXPERIMENTAL
Intervention: Concept mapping education
Number of subjects: 100
Study 34158793 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based education
Number of subjects: 100
Study 32011701 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week web-based intervention (with or without initial face-to-face measure)
Number of subjects: 0
Study 32011701 — intervention group
Group type: COMPARATOR
Intervention: Control condition (regular school lessons following the curriculum)
Number of subjects: 0
Study 32915427 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow tongue coating (YTC) patients
Number of subjects: 41
Study 32915427 — intervention group
Group type: EXPERIMENTAL
Intervention: White tongue coating (WTC) patients
Number of subjects: 41
Study 32915427 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 41
Study 33755582 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi‐tetanus toxoid conjugate vaccine (Typhoid Vaccine Acceleration Consortium: TyVAC)
Number of subjects: 1
Study 35069728 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNMES
Number of subjects: 44
Study 35069728 — intervention group
Group type: COMPARATOR
Intervention: NMES
Number of subjects: 44
Study 34278040 — intervention group
Group type: EXPERIMENTAL
Intervention: DualStim therapy with intracavernosal injection of Wharton's Jelly (WJ)
Number of subjects: 60
Study 34278040 — intervention group
Group type: COMPARATOR
Intervention: DualStim therapy with saline (control)
Number of subjects: 60
Study 35704302 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary catheter placement
Number of subjects: 491
Study 35704302 — intervention group
Group type: COMPARATOR
Intervention: No urinary catheter placement
Number of subjects: 491
Study 32833109 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine administration prior to CA procedure
Number of subjects: 550
Study 32833109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no N-acetylcysteine)
Number of subjects: 550
Study 32833109 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine administration
Number of subjects: 550
Study 36377202 — intervention group
Group type: EXPERIMENTAL
Intervention: Journey to Social Inclusion (J2SI) program
Number of subjects: 135
Study 36377202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health professional support
Number of subjects: 135
Study 36377202 — intervention group
Group type: EXPERIMENTAL
Intervention: Housed at 12 months
Number of subjects: 135
Study 36377202 — intervention group
Group type: COMPARATOR
Intervention: Standard service provision
Number of subjects: 135
Study 34867116 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted local anesthesia injection
Number of subjects: 72
Study 34867116 — intervention group
Group type: COMPARATOR
Intervention: Traditional manual injection of local anesthesia
Number of subjects: 72
Study 32113031 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratafix Symmetric (triclosan-coated barbed suture)
Number of subjects: 139
Study 32113031 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS plus (triclosan-coated polydioxanone loop suture)
Number of subjects: 139
Study 32113031 — intervention group
Group type: COMPARATOR
Intervention: PDS (polydioxanone loop suture)
Number of subjects: 139
Study 35366801 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Lumen Tube (DLT)
Number of subjects: 74
Study 35366801 — intervention group
Group type: COMPARATOR
Intervention: EZ-bronchial blocker (EZB)
Number of subjects: 74
Study 33752724 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Oblique Incision (MOI)
Number of subjects: 62
Study 33752724 — intervention group
Group type: COMPARATOR
Intervention: Classic Oblique Incision (COI)
Number of subjects: 62
Study 36401476 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation with red and infrared laser with local application on the pain points (808 nm and 660 nm, 100 mW, 6 J per point)
Number of subjects: 0
Study 36401476 — intervention group
Group type: COMPARATOR
Intervention: Photobiomodulation with red laser with transcutaneous application on the radial artery (660 nm, 100 mW, 30 minutes)
Number of subjects: 0
Study 32374123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin succinate in the early postoperative period (G1A)
Number of subjects: 160
Study 32374123 — intervention group
Group type: COMPARATOR
Intervention: No solifenacin treatment (G1B)
Number of subjects: 160
Study 32374123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg solifenacin succinate in the early postoperative period (G2A)
Number of subjects: 160
Study 32374123 — intervention group
Group type: COMPARATOR
Intervention: No solifenacin treatment (G2B)
Number of subjects: 160
Study 35942131 — intervention group
Group type: EXPERIMENTAL
Intervention: Early multidisciplinary collaborative intervention (Res; n=55)
Number of subjects: 95
Study 35942131 — intervention group
Group type: COMPARATOR
Intervention: Routine early rehabilitation intervention (Con; n=40)
Number of subjects: 95
Study 34583751 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 350
Study 34583751 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 350
Study 32677992 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab
Number of subjects: 0
Study 32677992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36097258 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin (200μg/kg body weight) twice, one week apart
Number of subjects: 224
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl benzoate (25% or 10%) upon repeated application
Number of subjects: 224
Study 36097258 — intervention group
Group type: COMPARATOR
Intervention: Oral ivermectin upon repeated application
Number of subjects: 224
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl benzoate upon repeated application
Number of subjects: 224
Study 36097258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzyl benzoate
Number of subjects: 224
Study 33096946 — intervention group
Group type: EXPERIMENTAL
Intervention: Two ipsilateral Double‐J stents (7F each)
Number of subjects: 70
Study 33096946 — intervention group
Group type: COMPARATOR
Intervention: One Double‐J stent (7F)
Number of subjects: 70
Study 33313736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of self-care CIH therapies (tai chi/qi gong, yoga, meditation) and practitioner-delivered CIH therapies (chiropractic care, acupuncture, therapeutic massage)
Number of subjects: 0
Study 33313736 — intervention group
Group type: COMPARATOR
Intervention: Practitioner-delivered CIH therapies alone (chiropractic care, acupuncture, therapeutic massage)
Number of subjects: 0
Study 33313736 — intervention group
Group type: COMPARATOR
Intervention: Self-care CIH therapies alone (tai chi/qi gong, yoga, meditation)
Number of subjects: 0
Study 34783204 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC (hyperthermic intraperitoneal chemotherapy) at 42°C (41.5°C‐42.5°C)
Number of subjects: 80
Study 34783204 — intervention group
Group type: COMPARATOR
Intervention: NIPEC (normothermic intraperitoneal chemotherapy) at 37°C (36.5°C‐37.5°C)
Number of subjects: 80
Study 34783204 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 80
Study 34783204 — intervention group
Group type: COMPARATOR
Intervention: NIPEC
Number of subjects: 80
Study 34783204 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC/NIPEC
Number of subjects: 80
Study 34542553 — intervention group
Group type: COMPARATOR
Intervention: Incentives of $0, $200, or $500 for the smoking cessation trial
Number of subjects: 1296
Study 34542553 — intervention group
Group type: COMPARATOR
Intervention: Incentives of $0, $100, or $300 for the ambulation trial
Number of subjects: 1296
Study 36041869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP control (mean SBP 129.7 mm Hg)
Number of subjects: 164
Study 36041869 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP control (mean SBP 138.3 mm Hg)
Number of subjects: 164
Study 32897208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound subgingival scaling combined with manual root planing
Number of subjects: 40
Study 32897208 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound subgingival scaling
Number of subjects: 40
Study 35779139 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal hybrid training of ASHAs (1 day in-person classroom training and seven online sessions)
Number of subjects: 75
Study 35779139 — intervention group
Group type: COMPARATOR
Intervention: Traditional one-day in-person classroom training
Number of subjects: 75
Study 34326185 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (4,000 IU) plus low-dose inhaled fluticasone propionate
Number of subjects: 176
Study 34326185 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 176
Study 32030526 — intervention group
Group type: EXPERIMENTAL
Intervention: Free rapid HIV self-test kits
Number of subjects: 114
Study 36464918 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido (DN)
Number of subjects: 2
Study 36464918 — intervention group
Group type: COMPARATOR
Intervention: Custodiol cardioplegia (CC)
Number of subjects: 2
Study 33684892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretense activity related to the story
Number of subjects: 60
Study 33684892 — intervention group
Group type: COMPARATOR
Intervention: Non-pretense activity related to the story
Number of subjects: 60
Study 33684892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fantastical story
Number of subjects: 60
Study 33684892 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic story
Number of subjects: 60
Study 32434996 — intervention group
Group type: EXPERIMENTAL
Intervention: OIL (1.18 g/kg, rich in MUFA)
Number of subjects: 16
Study 32434996 — intervention group
Group type: COMPARATOR
Intervention: VCL (water)
Number of subjects: 16
Study 35439029 — intervention group
Group type: EXPERIMENTAL
Intervention: Navicixizumab (3 mg/kg or 4 mg/kg once every 2 weeks) plus Paclitaxel (80 mg/m2 intravenously on days 0, 7, and 14 of 28-day cycles)
Number of subjects: 44
Study 35439029 — intervention group
Group type: EXPERIMENTAL
Intervention: Navicixizumab plus Paclitaxel
Number of subjects: 44